Chinese Journal of Antituberculosis ›› 2026, Vol. 48 ›› Issue (5): 621-630.doi: 10.19982/j.issn.1000-6621.20250433
• Original Articles • Previous Articles Next Articles
Tong Jing1, Liu Kewei1, Guo Can2, Shi Jin1, Pang Yu3(
), Gao Mengqiu1(
), Li Shanshan3(
)
Received:2025-11-06
Online:2026-05-10
Published:2026-04-27
Contact:
Pang Yu,Gao Mengqiu,Li Shanshan
E-mail:pangyupound@163.com;gaomqwdm@aliyun.com;lss9011@126.com
Supported by:CLC Number:
Tong Jing, Liu Kewei, Guo Can, Shi Jin, Pang Yu, Gao Mengqiu, Li Shanshan. Expression and clinical significance of co-signaling molecules on surface of T lymphocytes in different states of Mycobacterium tuberculosis infection[J]. Chinese Journal of Antituberculosis, 2026, 48(5): 621-630. doi: 10.19982/j.issn.1000-6621.20250433
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20250433
| 特征 | HC组(22名) | LTBI组(20例) | TB组(22例) | 统计检验值 | P值 |
|---|---|---|---|---|---|
| 年龄[岁,M(Q1,Q3)] | 31.50(30.05,40.25) | 43.50(33.00,52.00) | 41.50(31.75,55.25) | H=5.561 | 0.061 |
| 性别[名/例(构成比,%)] | χ2=2.716 | 0.257 | |||
| 男性 | 9(40.9) | 7(35.0) | 13(59.1) | ||
| 女性 | 13(59.1) | 13(65.0) | 9(40.9) | ||
| BMI[kg/m2,M(Q1,Q3)] | 24.69(23.49,26.55) | 25.39(23.79,26.88) | 26.08(28.81,26.82) | H=1.805 | 0.406 |
| BCG接种史[名/例(接种率,%)] | 22(100.0) | 20(100.0) | 21(95.5) | χ2=1.939 | 0.379 |
| IGRA阳性[名/例(阳性率,%)] | 0(0.0) | 20(100.0) | 22(100.0) | χ2=64.000 | <0.001 |
| 指标 | TB组(22例) | LTBI组(20例) | HC组(22名) | 统计检验值 | P值a | 统计检验值 | P值b | 统计检验值 | P值c | 统计检验值 | P值d |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD3+ | 53.23±16.15 | 61.47±10.12 | 65.59±13.94 | F=4.467 | 0.016 | q=2.703 | 0.144 | q=4.156 | 0.013 | q=1.352 | 0.607 |
| CD4+ | 33.06±9.58 | 34.90±7.64 | 40.39±11.01 | F=3.480 | 0.037 | q=0.878 | 0.809 | q=3.594 | 0.036 | q=2.629 | 0.159 |
| Th1 | 3.05 (1.33,4.16) | 8.50 (1.76,15.28) | 5.72 (2.63,16.33) | H=9.416 | 0.009 | Z=2.566 | 0.031 | Z=2.721 | 0.020 | Z=0.089 | >0.999 |
| Th2 | 6.62 (3.01,9.57) | 5.36 (4.94,6.30) | 4.61 (3.73,5.86) | H=4.631 | 0.099 | Z=0.698 | >0.999 | Z=2.117 | 0.103 | Z=1.368 | 0.514 |
| Th1/Th2 | 0.35 (0.49,3.04) | 1.40 (0.38,2.57) | 1.38 (0.50,3.04) | H=11.49 | 0.003 | Z=2.474 | 0.040 | Z=3.231 | 0.004 | Z=0.679 | >0.999 |
| Th9 | 0.30 (0.03,2.36) | 0.15 (0.06,0.25) | 0.05 (0.03,0.27) | H=5.136 | 0.077 | Z=0.474 | >0.999 | Z=2.166 | 0.091 | Z=1.639 | 0.303 |
| Th17 | 0.12 (0.05,0.74) | 0.68 (0.14,2.22) | 0.46 (0.06,1.93) | H=4.765 | 0.092 | Z=2.138 | 0.098 | Z=1.426 | 0.462 | Z=0.747 | >0.999 |
| Th22 | 0.04 (0.01,0.18) | 0.45 (0.09,1.62) | 0.39 (0.01,0.83) | H=16.520 | <0.001 | Z=4.061 | <0.001 | Z=2.275 | 0.069 | Z=1.812 | 0.210 |
| Treg | 9.85±3.08 | 8.74±2.00 | 7.37±2.09 | F=4.596 | 0.014 | q=1.102 | 0.275 | q=3.003 | 0.012 | q=1.829 | 0.140 |
| 指标 | TB组(22例) | LTBI组(20例) | HC组(22名) | 统计检验值 | P值a | 统计检验值 | P值b | 统计检验值 | P值c | 统计检验值 | P值d |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD8+ | 16.88±7.59 | 24.56±7.09 | 24.07±8.86 | F=6.392 | 0.003 | q=4.450 | 0.007 | q=4.267 | 0.010 | q=0.285 | 0.978 |
| Tc1 | 5.34 (2.05,18.33) | 12.74 (4.10,37.56) | 18.47 (2.90,40.94) | H=4.196 | 0.123 | Z=1.496 | 0.404 | Z=1.951 | 0.153 | Z=0.409 | >0.999 |
| Tc2 | 1.95 (0.79,3.87) | 1.18 (0.73,2.05) | 0.76 (0.40,1.58) | H=5.901 | 0.052 | Z=0.935 | >0.990 | Z=2.409 | 0.048 | Z=1.434 | 0.455 |
| Tc1/Tc2 | 1.72 (0.37,3.15) | 4.67 (0.70,11.14) | 13.29 (1.55,20.41) | H=8.377 | 0.015 | Z=1.354 | 0.528 | Z=2.893 | 0.011 | Z=1.380 | 0.503 |
| Tc9 | 0.06 (0.01,0.24) | 0.00 (0.00,0.08) | 0.01 (0.00,0.33) | H=4.717 | 0.095 | Z=2.055 | 0.120 | Z=1.617 | 0.318 | Z=0.477 | >0.999 |
| Tc17 | 0.02 (0.00,0.06) | 0.08 (0.01,0.12) | 0.03 (0.00,0.08) | H=5.947 | 0.051 | Z=2.364 | 0.054 | Z=0.630 | >0.999 | Z=1.749 | 0.241 |
| Tc22 | 0.01 (0.00,0.06) | 0.05 (0.02,0.13) | 0.02 (0.01,0.07) | H=4.708 | 0.095 | Z=2.068 | 0.116 | Z=0.434 | >0.999 | Z=1.644 | 0.301 |
| 指标 | TB组(22例) | LTBI组(20例) | HC组(22名) | 统计检验值 | P值a | 统计检验值 | P值b | 统计检验值 | P值c | 统计检验值 | P值d | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTLA-4 | 0.42 (0.21,1.92) | 0.14 (0.07,0.20) | 0.20 (0.14,0.34) | H=20.790 | <0.001 | Z=4.548 | <0.001 | Z=2.503 | 0.037 | Z=2.105 | 0.106 | |||||||||||
| TIM-3 | 0.67 (0.36,0.88) | 0.80 (0.57,1.31) | 0.55 (0.48,0.68) | H=4.454 | 0.108 | Z=1.486 | 0.412 | Z=0.583 | >0.999 | Z=2.055 | 0.120 | |||||||||||
| BTLA | 19.83 (13.43,30.49) | 24.43 (20.33,30.41) | 17.92 (11.25,35.70) | H=1.818 | 0.403 | Z=1.012 | 0.934 | Z=0.283 | >0.999 | Z=1.289 | 0.592 | |||||||||||
| TIGIT | 12.92±5.13 | 20.87±6.11 | 13.93±5.28c | F=9.782 | <0.001 | q=4.903 | 0.003 | q=0.998 | 0.761 | q=5.877 | <0.001 | |||||||||||
| LAG-3 | 0.21 (0.07,0.44) | 0.25 (0.14,0.44) | 0.29 (0.18,0.72) | H=3.963 | 0.138 | Z=0.653 | >0.999 | Z=1.960 | 0.150 | Z=1.260 | 0.623 | |||||||||||
| PD-1 | 7.21 (4.20,9.26) | 8.33 (5.99,13.05) | 6.85 (4.21,8.80) | H=4.697 | 0.096 | Z=1.572 | 0.348 | Z=0.534 | >0.999 | Z=2.094 | 0.109 | |||||||||||
| CD160 | 0.00 (0.01,0.05) | 0.05 (0.03,0.08) | 0.08 (0.01,0.17) | H=7.177 | 0.028 | Z=2.146 | 0.096 | Z=2.447 | 0.043 | Z=0.242 | >0.999 | |||||||||||
| CRTAM | 0.04 (0.02,0.12) | 0.03 (0.01,0.04) | 0.02 (0.01,0.05) | H=3.691 | 0.158 | Z=1.274 | 0.608 | Z=1.877 | 0.182 | Z=0.557 | >0.999 | |||||||||||
| GITR | 2.34 (1.36,5.20) | 2.01 (1.64,3.80) | 1.48 (0.88,1.64) | H=11.580 | 0.003 | Z=0.261 | >0.999 | Z=2.834 | 0.014 | Z=3.027 | 0.007 | |||||||||||
| OX40 | 2.12 (0.75,5.16) | 1.90 (1.47,2.71) | 0.89 (0.45,2.24) | H=6.230 | 0.044 | Z=0.073 | >0.999 | Z=2.142 | 0.097 | Z=2.164 | 0.091 | |||||||||||
| 4-1BB | 0.03 (0.01,0.13) | 0.05 (0.02,0.10) | 0.03 (0.01,0.04) | H=5.701 | 0.058 | Z=1.128 | 0.778 | Z=1.259 | 0.624 | Z=2.384 | 0.051 | |||||||||||
| ICOS | 26.85±9.98 | 28.61±7.83 | 32.47±9.80 | F=2.593 | 0.078 | q=2.113 | 0.301 | q=3.152 | 0.074 | q=0.963 | 0.775 | |||||||||||
| CD40L | 0.07 (0.03,0.10) | 0.03 (0.02,0.06) | 0.02 (0.01,0.05) | H=8.902 | 0.012 | Z=2.217 | 0.080 | Z=2.825 | 0.014 | Z=0.539 | >0.999 | |||||||||||
| 指标 | TB组(22例) | LTBI组(20例) | HC组(22名) | 统计检验值 | P值a | 统计检验值 | P值b | 统计检验值 | P值c | 统计检验值 | P值d | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTLA-4 | 1.03 (0.22,1.63) | 0.08 (0.05,0.12) | 0.10 (0.04,0.46) | H=20.840 | <0.001 | Z=4.279 | <0.001 | Z=3.477 | 0.002 | Z=0.885 | >0.999 | |||||||||||
| TIM-3 | 1.37 (0.57,2.63) | 1.31 (0.60,1.89) | 0.86 (0.61,1.46) | H=1.742 | 0.419 | Z=0.631 | >0.999 | Z=1.320 | 0.561 | Z=0.657 | >0.999 | |||||||||||
| BTLA | 11.94 (7.04,18.35) | 11.58 (9.04,22.71) | 13.56 (8.48,27.12) | H=1.494 | 0.474 | Z=0.906 | >0.999 | Z=1.158 | 0.741 | Z=0.224 | >0.999 | |||||||||||
| TIGIT | 26.30± 10.91 | 33.11± 12.18 | 29.64± 16.25 | H=1.782 | 0.055 | q=1.361 | 0.603 | Z=1.341 | 0.612 | Z=2.669 | 0.151 | |||||||||||
| LAG-3 | 0.14 (0.06,0.34) | 0.16 (0.03,0.27) | 0.17 (0.08,0.22) | H=0.261 | 0.878 | Z=0.486 | >0.999 | Z=0.101 | >0.999 | Z=0.387 | >0.999 | |||||||||||
| PD-1 | 7.84 (4.74,15.11) | 8.10 (5.01,11.68) | 6.86 (5.00,7.85) | H=1.942 | 0.379 | Z=0.206 | >0.999 | Z=1.304 | 0.577 | Z=1.066 | 0.859 | |||||||||||
| CD160 | 1.53 (0.69,2.67) | 1.84 (1.01,3.11) | 1.41 (0.80,1.98) | H=1.988 | 0.370 | Z=0.702 | >0.999 | Z=0.724 | >0.999 | Z=1.409 | 0.476 | |||||||||||
| CRTAM | 0.10 (0.03,0.26) | 0.13 (0.07,0.31) | 0.06 (0.03,0.18) | H=3.420 | 0.181 | Z=1.081 | 0.840 | Z=0.783 | >0.999 | Z=1.844 | 0.196 | |||||||||||
| GITR | 0.74 (0.29,1.32) | 0.43 (0.18,0.85) | 0.41 (0.22,1.32) | H=1.955 | 0.376 | Z=1.365 | 0.517 | Z=0.931 | >0.999 | Z=0.456 | >0.999 | |||||||||||
| OX40 | 0.16 (0.05,0.46) | 0.06 (0.03,0.16) | 0.03 (0.01,0.09) | H=13.360 | 0.001 | Z=1.739 | 0.246 | Z=3.655 | <0.001 | Z=1.828 | 0.203 | |||||||||||
| 4-1BB | 0.01 (0.00,0.03) | 0.00 (0.00,0.03) | 0.01 (0.00,0.02) | H=0.314 | 0.854 | Z=0.443 | >0.999 | Z=0.516 | >0.999 | Z=0.061 | >0.999 | |||||||||||
| ICOS | 7.28 (4.46,16.56) | 5.44 (3.42,7.18) | 2.97 (1.48,5.54) | H=11.450 | 0.003 | Z=1.319 | 0.561 | Z=3.364 | 0.002 | Z=1.964 | 0.149 | |||||||||||
| CD40L | 0.00 (0.00,0.02) | 0.00 (0.00,0.01) | 0.00 (0.00,0.01) | H=0.367 | 0.832 | Z=0.543 | >0.999 | Z=0.499 | >0.999 | Z=0.056 | >0.999 | |||||||||||
| [1] | Houben RMGJ, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med, 2016, 13(10): e1002152. doi:10.1371/journal.pmed.1002152. |
| [2] | Menzies NA, Wolf E, Connors D, et al. Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions. Lancet Infect Dis, 2018, 18(8):e228-e238. doi:10.1016/S1473-3099(18)30134-8. |
| [3] | 屈燕, 李涛, 马文斌, 等. 世界卫生组织《2025年全球结核病报告》解读. 结核与肺部疾病杂志, 2025, 6(6): 613-623. doi:10.19983/j.issn.2096-8493.20250178. |
| [4] |
Jasenosky LD, Scriba TJ, Hanekom WA, et al. T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunol Rev, 2015, 264(1):74-87. doi:10.1111/imr.12274.
pmid: 25703553 |
| [5] | Sia JK, Rengarajan J. Immunology of Mycobacterium tuberculosis Infections. Microbiol Spectr, 2019, 7(4): 746. doi:10.1128/microbiolspec.GPP3-0022-2018. |
| [6] | Flynn JL, Chan J. Immunology of Tuberculosis. Annu Rev Immunol, 2001, 19(1):93-129. doi:10.1146/annurev.immunol.19.1.93. |
| [7] | Day CL, Abrahams DA, Bunjun R, et al. PD-1 Expression on Mycobacterium tuberculosis-Specific CD 4 T Cells Is Associated With Bacterial Load in Human Tuberculosis. Front Immunol, 2018, 9:1995. doi:10.3389/fimmu.2018.01995. |
| [8] |
Singh A, Mohan A, Dey AB, et al. Inhibiting the Programmed Death 1 Pathway Rescues Mycobacterium tuberculosis-Specific Interferon γ-Producing T Cells From Apoptosis in Patients With Pulmonary Tuberculosis. J Infect Dis, 2013, 208(4):603-615. doi:10.1093/infdis/jit206.
pmid: 23661793 |
| [9] | Samten B, Thomas EK, Gong J, et al. Depressed CD40 Ligand Expression Contributes to Reduced Gamma Interferon Production in Human Tuberculosis. Infect Immun, 2000, 68(5):3002-3006. doi:10.1128/IAI.68.5.3002-3006.2000. |
| [10] |
Kurachi M. CD8+ T cell exhaustion. Semin Immunopathol, 2019, 41(3):327-337. doi:10.1007/s00281-019-00744-5.
pmid: 30989321 |
| [11] | Kraehenbuehl L, Weng CH, Eghbali S, et al. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol, 2022, 19(1):37-50. doi:10.1038/s41571-021-00552-7. |
| [12] | World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022. |
| [13] |
Wherry EJ. T cell exhaustion. Nat Immunol, 2011, 12(6):492-499. doi:10.1038/ni.2035.
pmid: 21739672 |
| [14] | Choi Y, Shi Y, Haymaker CL, et al. T-cell agonists in cancer immunotherapy. J Immunother Cancer, 2020, 8(2):e000966. doi:10.1136/jitc-2020-000966. |
| [15] |
Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol, 2018, 18(2):91-104. doi:10.1038/nri.2017.112.
pmid: 28990586 |
| [16] | Hamashima R, Uchino J, Morimoto Y, et al. Association of immune checkpoint inhibitors with respiratory infections: A review. Cancer Treat Rev, 2020, 90:102109. doi:10.1016/j.ctrv.2020.102109. |
| [17] |
Gress AR, Ronayne CE, Thiede JM, et al. Recently activated CD4 T cells in tuberculosis express OX40 as a target for host-directed immunotherapy. Nat Commun, 2023, 14(1):8423. doi:10.1038/s41467-023-44152-8.
pmid: 38110410 |
| [18] | Zhao L, Cheng S, Fan L, et al. TIM-3: An update on immunotherapy. Int Immunopharmacol, 2021, 99:107933. doi:10.1016/j.intimp.2021.107933. |
| [19] |
Morgan J, Muskat K, Tippalagama R, et al. Classical CD4 T cells as the cornerstone of antimycobacterial immunity. Immunol Rev, 2021, 301(1):10-29. doi:10.1111/imr.12963.
pmid: 33751597 |
| [20] | Lai R, Williams T, Rakib T, et al. Heterogeneity in lung macrophage control of Mycobacterium tuberculosis is modulated by T cells. Nat Commun, 2024, 15(1):5710. doi:10.1038/s41467-024-48515-7. |
| [21] |
Wu Y, Zhang S, Peng W, et al. Changes in Lymphocyte Subsets in the Peripheral Blood of Patients with Active Pulmonary Tuberculosis. J Int Med Res, 2009, 37(6): 1742-1749. doi:10.1177/147323000903700610.
pmid: 20146872 |
| [22] |
Hernández-Pando R, Orozcoe H, Sampieri A, et al. Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology, 1996, 89(1): 26-33.
pmid: 8911136 |
| [23] |
Grotzke JE, Lewinsohn DM. Role of CD8+ T lymphocytes in control of Mycobacterium tuberculosis infection. Microbes Infect, 2005, 7(4):776-788. doi:10.1016/j.micinf.2005.03.001.
pmid: 15823514 |
| [24] | Brighenti S, Ordway DJ. Regulation of Immunity to Tuberculosis. Microbiol Spectr, 2016, 4(6). doi:10.1128/microbiolspec.TBTB2-0006-2016. |
| [25] | Cardona P, Cardona PJ. Regulatory T Cells in Mycobacterium tuberculosis Infection. Front Immunol, 2019, 10:2139. doi:10.3389/fimmu.2019.02139. |
| [26] |
Van Coillie S, Wiernicki B, Xu J. Molecular and Cellular Functions of CTLA-4. Adv Exp Med Biol, 2020, 1248:7-32. doi:10.1007/978-981-15-3266-5_2.
pmid: 32185705 |
| [27] | Baldanzi G. Immune Checkpoint Receptors Signaling in T Cells. Int J Mol Sci, 2022, 23(7):3529. doi:10.3390/ijms23073529. |
| [28] |
Harjunpää H, Guillerey C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol, 2020, 200(2):108-119. doi:10.1111/cei.13407.
pmid: 31828774 |
| [29] |
Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity, 2016, 44(5):989-1004. doi:10.1016/j.immuni.2016.05.001.
pmid: 27192565 |
| [30] |
Cai G, Freeman GJ. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol Rev, 2009, 229(1):244-258. doi:10.1111/j.1600-065X.2009.00783.x.
pmid: 19426226 |
| [31] | Piotrowska M, Spodzieja M, Kuncewicz K, et al. CD160 protein as a new therapeutic target in a battle against autoimmune, infectious and lifestyle diseases. Analysis of the structure, interactions and functions. Eur J Med Chem, 2021, 224:113694. doi:10.1016/j.ejmech.2021.113694. |
| [32] | Riccardi C, Ronchetti S, Nocentini G. Glucocorticoid-induced TNFR-related gene (GITR) as a therapeutic target for immunotherapy. Expert Opin Ther Targets, 2018, 22(9):783-797. doi:10.1080/14728222.2018.1512588. |
| [33] |
Knee DA, Hewes B, Brogdon JL. Rationale for anti-GITR cancer immunotherapy. Eur J Cancer, 2016, 67:1-10. doi:10.1016/j.ejca.2016.06.028.
pmid: 27591414 |
| [34] | Hassan GS, Salti S, Mourad W. Novel Functions of Integrins as Receptors of CD154: Their Role in Inflammation and Apoptosis. Cells, 2022, 11(11):1747. doi:10.3390/cells11111747. |
| [35] | Tang T, Cheng X, Truong B, et al. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacol Ther, 2021, 219:107709. doi:10.1016/j.pharmthera.2020.107709. |
| [36] |
Fu Y, Lin Q, Zhang Z, et al. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm Sin B, 2020, 10(3):414-433. doi:10.1016/j.apsb.2019.08.010.
pmid: 32140389 |
| [37] | Mousavi SF, Soroosh P, Takahashi T, et al. OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells. J Immunol, 2008, 181(9):5990-6001. doi:10.4049/jimmunol.181.9.5990. |
| [38] | Hodgson R, Christiansen D, Ierino F, et al. Inducible Co-Stimulator (ICOS) in transplantation: A review. Transplant Rev (Orlando), 2022, 36(4):100713. doi:10.1016/j.trre.2022.100713. |
| [39] | Shen X, Zhang J, Tang P, et al. Expression and clinical significance of B and T lymphocyte attenuator on CD4+ and CD8+ T cells from patients with pulmonary tuberculosis. Indian J Pathol Microbiol, 2019, 62(2): 232. doi:10.4103/IJPM.IJPM_727_17. |
| [40] | Yi L, Yan J, Wei P, et al. The levels of soluble CD137 are increased in tuberculosis patients and associated with disease severity and prognosis. Eur J Immunol, 2024, 54(8):e2350796. doi:10.1002/eji.202350796. |
| [1] | Gao Li, Zhang Guoqin. Current status and optimization paths of latent tuberculosis infection screening in patients with rheumatic immune diseases in China [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 561-566. |
| [2] | Wang Yongbing, Zhong Yuexiang, Fu Xiuying, Zhang Ying, Weng Wenpei, Zhou Fangjing, Yang Yingzhou, Luo Jilun. Survey of Mycobacterium tuberculosis infection rate and analysis of associated factors among three priority populations in Yingde’s zero-TB community pilot areas,Guangdong Province [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 468-476. |
| [3] | Liu Shuya, Zhang Ting, Wang Qingya, Fan Jun, Wang Ni. Analysis of close contacts screening situation and time changing trends of pulmonary tuberculosis patients in Chongqing from 2015 to 2024 [J]. Chinese Journal of Antituberculosis, 2026, 48(2): 230-237. |
| [4] | Zhou Cang, Li Guoli, Jiang Hui, Shao Yan, Song Honghuan, Xue Hao, Ning Jingxian, Pan Yuchen, Fei Xinru, Sun Zheng, Chen Cheng, Zhu Limei, Liu Qiao. Evaluation of the diagnostic efficacy of AIMTB-fluorescent immunochromatography for screening latent tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2026, 48(2): 289-298. |
| [5] | Shang Yuanyuan, Nie Wenjuan, Chu Naihui. Comparison of clinical characteristics and prognostic factors between elderly and non-elderly patients with Mycobacterium abscessus pulmonary disease [J]. Chinese Journal of Antituberculosis, 2026, 48(1): 106-112. |
| [6] | Tan Xiao, Li Fangping, Zhang Qian, Zhang Meijia. Causal effects of gut microbiota on non-tuberculous mycobacterial lung infection: a bidirectional two-sample mendelian randomization study [J]. Chinese Journal of Antituberculosis, 2026, 48(1): 121-130. |
| [7] | Fan Ruifang, Dai Xiaowei, Yang Xinyu, Chen Shuangshuang, Chen Hao, Yu Lan, Zhao Yanfeng, Li Chuanyou, Wang Nenhan. A study on the identification of Mycobacterium species using fluorescent PCR probe melting curve technique and DNA microarray chip technique [J]. Chinese Journal of Antituberculosis, 2025, 47(8): 1031-1037. |
| [8] | Nontuberculous Mycobacterial Diseases Branch of Chinese Antituberculosis Association. Expert consensus on molecular biology diagnosis of nontuberculous mycobacteria diseases [J]. Chinese Journal of Antituberculosis, 2025, 47(8): 961-975. |
| [9] | Li Longfen, Shi Chunjing, Luo Yun, Zhang Huajie, Liu Jun, Wang Ge, Zhao Yanhong, Yuan Lijuan, Li Shan, Li Wenming, Shen Lingjun. Establishing and validating a prediction model for HIV-associated nontuberculous mycobacterial disease based on machine learning [J]. Chinese Journal of Antituberculosis, 2025, 47(6): 708-718. |
| [10] | Qi Qi, Wang Zihao, Ye Linlin, Peng Wenbei, Zhou Qiong. Immune checkpoint inhibitors and tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(6): 792-797. |
| [11] | Ying Guangzhi, Cai Qingshan, Ma Xiaoqing, Chen Lingyan, Chen Yuanyuan. Diagnostic value of Nanopore targeted sequencing for detecting nontuberculous mycobacteria in respiratory specimens [J]. Chinese Journal of Antituberculosis, 2025, 47(5): 589-596. |
| [12] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
| [13] | Feng Yinping, Zhang Zunjing, Cai Qiujie, Wang Xiaomeng, Ma Yan, Liu Zhongda, Gao Lei. Exploring diagnostic and therapeutic approaches for latent tuberculosis infection based on the theory of hidden pathogen (Fu Xie) [J]. Chinese Journal of Antituberculosis, 2025, 47(10): 1249-1253. |
| [14] | Shi Xiaojing, Wang Xin, Guo Jianhua, Zhao Qingran, Wang Yuhan. Research on influencing factors of preventive treatment of latent tuberculosis infection based on thematic analysis:Taking Shijiazhuang City as an example [J]. Chinese Journal of Antituberculosis, 2025, 47(10): 1326-1332. |
| [15] | Zhong Lingshan, Wang Li, Zhang Shuo, Li Nan, Yang Qingyuan, Ding Wenlong, Chen Xingzhi, Huang Chencui, Xing Zhiheng. A machine learning model based on CT images combined with radiomics and semantic features for diagnosis of nontuberculous mycobacterium lung disease and pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1042-1049. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.